[go: up one dir, main page]

SG11201507608PA - Toxoid, compositions and related methods - Google Patents

Toxoid, compositions and related methods

Info

Publication number
SG11201507608PA
SG11201507608PA SG11201507608PA SG11201507608PA SG11201507608PA SG 11201507608P A SG11201507608P A SG 11201507608PA SG 11201507608P A SG11201507608P A SG 11201507608PA SG 11201507608P A SG11201507608P A SG 11201507608PA SG 11201507608P A SG11201507608P A SG 11201507608PA
Authority
SG
Singapore
Prior art keywords
toxoid
compositions
related methods
methods
Prior art date
Application number
SG11201507608PA
Inventor
Steven Hauser
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of SG11201507608PA publication Critical patent/SG11201507608PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SG11201507608PA 2013-03-15 2014-03-14 Toxoid, compositions and related methods SG11201507608PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361790423P 2013-03-15 2013-03-15
PCT/US2014/029035 WO2014144567A2 (en) 2013-03-15 2014-03-14 Toxoid, compositions and related methods

Publications (1)

Publication Number Publication Date
SG11201507608PA true SG11201507608PA (en) 2015-10-29

Family

ID=50489430

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201507608PA SG11201507608PA (en) 2013-03-15 2014-03-14 Toxoid, compositions and related methods

Country Status (13)

Country Link
US (2) US20160045586A1 (en)
EP (1) EP2968507A2 (en)
JP (1) JP2016516721A (en)
KR (1) KR20150133770A (en)
CN (1) CN105338997A (en)
AR (1) AR095669A1 (en)
AU (1) AU2014228956A1 (en)
BR (1) BR112015023332A2 (en)
CA (1) CA2907154A1 (en)
HK (1) HK1213800A1 (en)
SG (1) SG11201507608PA (en)
TW (1) TWI624474B (en)
WO (1) WO2014144567A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2969952T3 (en) 2011-04-22 2024-05-23 Wyeth Llc Compositions related to a mutant Clostridium difficile toxin and their procedures
BR122016023101B1 (en) 2012-10-21 2022-03-22 Pfizer Inc Polypeptide, immunogenic composition comprising it, as well as recombinant cell derived from Clostridium difficile
BR112015031088A2 (en) 2013-06-14 2017-07-25 Sanofi Pasteur Inc immunization compositions and methods against c. difficile
WO2016187073A1 (en) * 2015-05-15 2016-11-24 Sanofi Pasteur Inc. Methods for immunizing against clostridium difficile
BR112019024412A2 (en) 2017-06-09 2020-07-14 Hipra Scientific, S.L.U. IMMUNOGENIC COMPOSITION AND VACCINE USES UNDERSTANDING CLOSTRIDIUM DIFFICILE TOXIDES TO TREAT AND / OR PREVENT DISEASE CAUSED BY CLOSTRIDIUM SP, IMMUNOGENIC COMPOSITION AND VACCINE UNDERSTANDING C. THAT UNDERSTANDS SUCH IMMUNOGENIC COMPOSITION
US10096313B1 (en) * 2017-09-20 2018-10-09 Bose Corporation Parallel active noise reduction (ANR) and hear-through signal flow paths in acoustic devices
CA3239621A1 (en) * 2021-12-06 2023-06-15 Scott C. Kachlany Compositions and methods for treating cancer
WO2024160901A1 (en) 2023-02-02 2024-08-08 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US5610023A (en) * 1995-03-31 1997-03-11 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP1024826B1 (en) * 1997-10-20 2005-03-16 Acambis, Inc. Passive immunization against clostridium difficile disease
US6669520B2 (en) 2001-09-19 2003-12-30 United Microelectronics Corp. Method of fabricating an LC panel
KR101540920B1 (en) 2007-07-26 2015-08-03 사노피 파스퇴르 리미티드 Antigen-adjuvant compositions and methods
CN106039299A (en) * 2007-09-14 2016-10-26 赛诺菲巴斯德生物制剂有限责任公司 Pharmaceutical compositions containing Clostridium difficile toxoids A and B
GB201011968D0 (en) * 2010-07-16 2010-09-01 Secr Defence Toxoiding method

Also Published As

Publication number Publication date
KR20150133770A (en) 2015-11-30
TW201514197A (en) 2015-04-16
EP2968507A2 (en) 2016-01-20
JP2016516721A (en) 2016-06-09
US20160045586A1 (en) 2016-02-18
WO2014144567A2 (en) 2014-09-18
CN105338997A (en) 2016-02-17
CA2907154A1 (en) 2014-09-18
AU2014228956A1 (en) 2015-10-08
HK1213800A1 (en) 2016-07-15
AR095669A1 (en) 2015-11-04
BR112015023332A2 (en) 2017-08-22
US20180028637A1 (en) 2018-02-01
TWI624474B (en) 2018-05-21
WO2014144567A3 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
IL273205A (en) Compositions and methods
GB2533892B (en) Compositions and methods
EP2953474A4 (en) Compositions and methods
IL286759A (en) Therapeutic methods and compositions
ZA201603237B (en) Pesticidal compositions and related methods
SMT201900635T1 (en) Compositions and methods for activating
GB201308072D0 (en) Compositions and methods
EP2951283A4 (en) Compositions and methods
IL245035A0 (en) Pesticidal compositions and related methods
ZA201603227B (en) Pesticidal compositions and related methods
SG11201507608PA (en) Toxoid, compositions and related methods
ZA201603229B (en) Pesticidal compositions and related methods
GB201305813D0 (en) Compositions and methods
IL276126B (en) Compositions comprising l-4-chlorokynurenine and uses thereof
PL2988764T3 (en) Anti-dandruff compositions, and methods of use thereof
IL245034A0 (en) Pesticidal compositions and related methods
EP2964610A4 (en) Vinylsulfone-based 18f-labeling compositions and methods and uses thereof
ZA201603241B (en) Pesticidal compositions and related methods
ZA201600015B (en) Anti-fibrogenic compounds, methods and uses thereof
PT3066199T (en) Snorna, compositions and uses
SG11201604904XA (en) Detergent and rinse-aid compositions and methods
EP2952519A4 (en) Protopanoxadiol derivative, preparation method thereof and application thereof
SG11201507578PA (en) Toxoid, compositions and related methods
EP2980096A4 (en) 2 ,3 ,5 -trihydroxy-androst-6-one and preparation methods and use thereof
GB201322617D0 (en) Methods and compositions